… for Webinar Volunteering for Parkinson’s Research: What to Know and Expect First Name   Last Name   Email   Postal … had PD I am a researcher, clinician or work with the PD community Other   Diagnosis Date ${selected} Jan Feb Mar Apr … panelists discuss different types of clinical research and how to find the best study for you. We cover potential …

… The European Union recently awarded a $6 million grant to Herantis Pharma  for a Phase I-II clinical study of a … in the brain by targeting the neurons that produce it; however, as the disease progresses, these drugs may become less effective as more dopamine-producing cells become …

… accumulation of misfolded pathologic alpha-synuclein. This toxic alpha-synuclein moves between neurons and causes progressive neuronal death. Blocking entry of the toxic alpha-synuclein into neurons with an antibody (immune … this antibody may advance into clinical trial testing. Next Steps for Development: The antibody would …

… won praise for making its clinical trial data available to scientists around the world. Yes, the same company that makes your baby shampoo and BAND-AIDs® has a … our word for it.’” With this emerging trend of open access, however, by allowing others to dive into their “failures” or …

… One drug they found is called salbutamol, which is used to treat asthma. Partnering with the University of Bergen in … disease (PD). What's next? This is a strong lead on how to prevent PD, but researchers may have to tweak them to … trials acting against alpha-synuclein. Read more for the latest on those studies. These findings are another example of …

… this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval for its drug Nuplazid (the compound pimavanserin) for the treatment of psychosis … Acadia’s Nuplazid offers a new option. A Phase III study showed the drug significantly reduced psychosis compared to …